Inflammation Following Percutaneous Coronary Interventions Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital.

Slides:



Advertisements
Similar presentations
Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.
Advertisements

Pathologic Intimal Hyperplasia as a Response to Vascular Injury and Reconstruction.
Pleiotropic Effects of Statins Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
Acute Coronary Syndromes and The Inflammation Theory: Fact or Fiction Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Saint-Joseph University.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
Can we prevent stent restenosis after coronary stent implantation
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.
Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
PCI VS CABG JOURNAL REVIEW
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =
ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating.
ADVANCE ANGIOPLASTY 2004 LONDON, Jan LATEST CLINICAL EVIDENCE WITH DEXAMET GERMANO DI SCIASCIO, MD, FACC, FESC Professor and Chairman of Cardiology,
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Germano Di Sciascio, MD, FACC, FESC Professor & Chairman of.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
C. Michael Gibson, MS, MD Beth Israel Deaconess Medical Center Boston, MA The Benefit of Statin Therapy Before and After Coronary Revascularization.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
4S: Scandinavian Simvastatin Survival Study
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pregnancy-associated plasma protein-A levels in.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Local Release of C-Reactive Protein From Vulnerable.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Value of Platelet Reactivity in Predicting Response.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Vascular Inflammation and Repair: Implications for.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.
The American College of Cardiology Presented by Dr. Nikolaus Marx
The SELECT-ACS Trial Montreal Heart Institute
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Oxford Niacin Trial.
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Focus: Lipids and the endothelium
European Heart Association Journal 2007 April
Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L
Giuseppe Biondi Zoccai, MD
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
Erasmus MC, Thoraxcenter
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Pascal Meier, M. D. ; Rainer Zbinden, M. D. ; Mario Togni, M. D
Maintenance of Long-Term Clinical Benefit with
The American College of Cardiology Presented by Dr. Nikolaus Marx
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Presentation transcript:

Inflammation Following Percutaneous Coronary Interventions Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital

Inflammation Following Percutaneous Coronary Interventions Inflammation in coronary artery disease Inflammation in coronary artery disease PCI induce systemic inflammation PCI induce systemic inflammation Relation between PCI, inflammation and restenosis Relation between PCI, inflammation and restenosis Determinant of the inflammatory response following PCI Determinant of the inflammatory response following PCI Anti-inflammatory therapy in the setting of PCI Anti-inflammatory therapy in the setting of PCI

Unstable Plaques are Hot. CRP probably identifies vulnerable plaques Difference of temp from background temp Stefanadis. Circ 99;99:1965

CRP Is a Risk Factor in Unstable Angina Liuzzo et al. N Engl J Med. 1994;331:417. CRP <0.3 mg/dL (n=11) CRP ≥0.3 mg/dL (n=20) p-value Ischemic episodes1.8±2.44.8± In-hospital events: Death02 MI05 Revascularization212 Total2 (18%)18 (90%)<0.001

Inflammation Following Percutaneous Coronary Interventions Inflammation in coronary artery disease Inflammation in coronary artery disease PCI induce systemic inflammation PCI induce systemic inflammation Relation between PCI, inflammation and restenosis Relation between PCI, inflammation and restenosis Determinant of the inflammatory response following PCI Determinant of the inflammatory response following PCI Anti-inflammatory therapy in the setting of PCI Anti-inflammatory therapy in the setting of PCI

Coronary Angioplasty Induces a Systemic Inflammatory Response Mean CRP mg/L P < P = NS Azar et al. Am J Cardiol 1997;80:1476-8

Median plasma levels of CRP before and following PCI Gaspardone et al. AJC 1998;82:515

Event-free survival in patients with normal or high CRP 72 hours following PCI Gaspardone et al. AJC 1998;82:515

Relationship between circulating monocytes and in- stent neointima proliferation following coronary stenting Coronary stent implantation of 107 patients Coronary stent implantation of 107 patients Blood collected prior to PCI and each of the 7 days following PCI Blood collected prior to PCI and each of the 7 days following PCI Moncotye count increased and reached its peak 48 hours after stent implantation Moncotye count increased and reached its peak 48 hours after stent implantation At 6-month follow-up, all patients received angiographic and volumetric intravascular ultrasound analysis At 6-month follow-up, all patients received angiographic and volumetric intravascular ultrasound analysis Fukuda et al. JACC 2004;43:18-23

Relationship between maximum monocyte count and in- stent neointimal volume after 6-month follow-up Fukuda et al. JACC 2004;43:18-23

Monocyte Activation and Binding to Endothelial Cells (CD11b-VICAM)

Leukocyte activation, adhesion and migration

Serial changes in CD11b and 8B2 on the surface of PMNs from the coronary sinus samples following PCI Inoue et al. Circ 2003;107:1757

PTCA results in platelets activation Serrano et al. J Am Coll Cardiol 1997;29:

The shedding of sCD40L during platelets stimulation

Effects of sCD40L Initiation of the inflammatory response – Expression of ICAM, VICAM, E-selectin – Expression of chemokines (IL-6, IL-6, MCP-1) Prothrombotic effect – Expression of tissue factor – Interaction with the GP IIb/IIIa receptor Progression of atherosclerosis

Soluble CD40 Ligand is a predictor of restenosis following PCI Cipollone et al. J Am Coll Cardiol 2003;108:

Inflammation Following Percutaneous Coronary Interventions Inflammation in coronary artery disease Inflammation in coronary artery disease PCI induce systemic inflammation PCI induce systemic inflammation Relation between PCI, inflammation and restenosis Relation between PCI, inflammation and restenosis Determinant of the inflammatory response following PCI Determinant of the inflammatory response following PCI Anti-inflammatory therapy in the setting of PCI Anti-inflammatory therapy in the setting of PCI

Severity of stent inflammation from pathology studies according to damage of the arterial wall by stent struts Farb et al. Circulation 1999;99:44-52

Clinical and procedural correlates with the inflammatory response following PCI ConditionCorrelation Vessel treatedNO Stent vs. balloonNO Maximal pressureNO No stentsNO AgeNO SexNO Baseline CRPYES Azar et al. Am J Cardiol 1997;80: Liuzzo et al. Circulation 1998;98:2370

Inflammation Following Percutaneous Coronary Interventions Inflammation in coronary artery disease Inflammation in coronary artery disease PCI induce systemic inflammation PCI induce systemic inflammation Relation between PCI, inflammation and restenosis Relation between PCI, inflammation and restenosis Determinant of the inflammatory response following PCI Determinant of the inflammatory response following PCI Anti-inflammatory therapy in the setting of PCI Anti-inflammatory therapy in the setting of PCI

IMPRESS: Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation Inclusion: – Single vessel stenting – CRP 0.5 mg/dL 72 hours after stenting Treatment: – Randomly assigned, double blinded – Prednisone: 1 mg/kg for the first 10 days, 0.5 mg/kg day , 0.25 mg/kg day End-Points: – 12-month event free survival (death, MI, repeat revascularization) Versaci et al. J Am Coll Cardiol 2002;40:1935

Event-free survival according to treatment in patients with CRP > 5 mg/dL 72 hours after PCI Versaci et al. J Am Coll Cardiol 2002;40:1935

Abiciximab improves the outcome of PCI: 3-year event-free survival from EPIC JAMA 1997;278:478

Effect of abciximab use on inflammatory markers’ rise following PCI P=0.025 P<0.001 P=0.12 Median change at 48-hour Lincoff et al. Circ 2001;104:

Abciximab decreases detectable CD11b on neutrophils from patients undergoing PCI Mickelson et al. J Am Coll Cardiol 1999;33:97-106

Mean elevations of CRP and IL-6 elevation following PCI in controls and in tirofiban users Azar et al. J Am Coll Cardiol 2003;supl A: Azar et al. Am Journal Cardiol; January 15, 2005

Effect of tirofiban on sCD40L rise (patients in the upper quartile of sCD40L at baseline excluded) Azar et al. Am Journal Cardiol; January 15, % inhibition

Statin therapy at the time of PCI confers an early and sustained survival benefit Chan et al. Circulation 2002;105:

Mortality according to baseline CRP and statins use following PCI 1-year mortality (%) P = NS P < Preprocedural CRP Chen et al. Circulation 2003;107:

Effects of Statin Therapy on the Rise of Markers of Inflammation and on Platelets Activation Following Angioplasty -64% P = Azar et al. Circulation, supplement, October 2004 Azar et al. Am Journal Cardiol; January 15, % P = NS

Statins suppress elevation of hs-CRP following angioplasty in patients with high levels of hs-CRP at baseline Azar et al. Circulation, supplement, October 2004 Azar et al. Am Journal Cardiol; January 15, 2005

Statins decrease CD11b expression and CD11b dependent adhesion of monocytes to endothelium in patients with hypercholesterolemia Weber et al. J Am Coll Cardiol 1997;30:1212

Conclusions PCI induce a systemic inflammatory response PCI induce a systemic inflammatory response The amplitude of this response correlates significantly with adverse events following PCI, especially restenosis The amplitude of this response correlates significantly with adverse events following PCI, especially restenosis This response depends mainly on the degree of damage inflicted to the arterial wall (media) and on the degree of plaque inflammation present before PCI This response depends mainly on the degree of damage inflicted to the arterial wall (media) and on the degree of plaque inflammation present before PCI Anti-inflammatory therapy may be beneficial in patients with high CRP following PCI Anti-inflammatory therapy may be beneficial in patients with high CRP following PCI Many drugs proven to be beneficial during PCI exhibit anti- inflammatory activity which probably contributes to their effectiveness Many drugs proven to be beneficial during PCI exhibit anti- inflammatory activity which probably contributes to their effectiveness

Non-fatal MI according to baseline CRP and statins use following PCI Pre-procedural CRP 1-year non-fatal MI (%) P = NS P = 0.09 P = 0.167

Revascularisation within 1 year according to baseline CRP and statins use following PCI Pre-procedural CRP 1-year revascularization rate (%) P = NS for all

Effects of tirofiban on CRP and IL-6 elevation following PCI Mean CRP change p = NS for all Mean IL-6 change p = NS for all placebo placebo tirofiban tirofiban Bonz et al. Am Heart J 2003;145:693-9

Maximum monocyte count following PCI is an independent predictor of in-stent neointimal volume at 6-month follow-up Regressionp value coefficient Age Male sex HTN Diabetes Hyperlipidemia Stent volume immediately after implantation0.423< Maximum monocyte count Fukuda et al. JACC 2004;43:18-23

The increase in CD11b at 48-hour is positively correlated with late lumen loss at 6-month follow up Inoue et al. Circ 2003;107:1757

Leukocyte-platelet complexes increase following PCI % of leukocytes highly bound to platelets P<0.05 P<0.05 Mickelson et al. J Am Coll Cardiol 1996;28:

Leukocyte-platelet aggregates are associated with increased adverse event rate following PCI Mickelson et al. J Am Coll Cardiol 1996;28:

SMC Proliferation Migration Matrix secretion SMC receptors Mechanism of Neointimal Formation Arterial injury Growth Factors & cytokines ThrombusInflammation G0G0 G1G1 G2G2 S M Smooth muscle cell (SMC) Signal transduction Cell cycle

Response of CRP and SAA to PTCA according to clinical status and baseline markers levels Liuzzo et al. Circulation 1998;98:2370

Inflammatory markers measured 24 hours after PCI are predictor of restenosis Cipollone et al. J Am Coll Cardiol 2003;108:

Sources of Inflammatory Markers

Risk of MI According to CRP Levels

IMPRESS Study: Clinical Outcome Prednisone therapy mainly reduces the incidence of TVR Event rate (%) Versaci et al. J Am Coll Cardiol 2002;40:1935

Effect of tirofiban on sCD40L rise following PCI Azar et al. Am Journal Cardiol; January 15, 2005